CoChat
Sign Up
Cited by 133

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

Mu, Yiming, Bao, Xiaolei, Eliaschewitz, Freddy G, Hansen, Morten Rix, Kim, Bom Taeck, Koroleva, Anna, Ma, Ronald C W, Yang, Tao, Zu, Ning, Liu, Ming·2024·The Lancet Diabetes & Endocrinology
DOI 10.1016/s2213-8587(23)00388-1
Open this paper in CoChat — free account

Abstract

Background Data on the benefits of the once weekly GLP-1 receptor agonist semaglutide 2·4 mg for weight management in people from east Asia are insufficient. The objective of this study was to determine the efficacy and safety of once weekly semaglutide 2·4 mg versus placebo for weight management in a predominantly east Asian adult population. Methods This randomised phase 3a, double-blind multicentre controlled trial (STEP 7) recruited participants from 23 hospitals and trial centres in China, Hong Kong, Brazil, and South Korea. Adults with overweight or obesity, with or without type 2 diabetes, were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks, plus a diet and physical activity intervention. Randomisation was done in blocks of six with an interactive web response system and was stratified by diagnosis of type 2 diabetes. Participants, investigators, and the trial sponsor were masked to treatment allocation until after database lock. Primary endpoints were percentage change in mean bodyweight and proportion of participants having reached a weight reduction of at least 5% of bodyweight from baseline to week 44. Safety was assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04251156, and is now complete. Findings From Dec 8, 2020, to Aug 23, 2022, 448 participants were screened, of whom 375 were randomly assigned to either…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(23)00388-1

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Research works printed but not linked: 15

  1. Pantalone, 2017, Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system, BMJ Open, 7, 10.1136/bmjopen-2017-017583 · DOI
  2. Zhou, 2002, Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population [In Chinese], Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 23, 5
  3. Pan, 2021, Epidemiology and determinants of obesity in China, Lancet Diabetes Endocrinol, 9, 373, 10.1016/S2213-8587(21)00045-0 · DOI
  4. Wang, 2021, Health policy and public health implications of obesity in China, Lancet Diabetes Endocrinol, 9, 446, 10.1016/S2213-8587(21)00118-2 · DOI · Paper page
  5. Hemmingsson, 2021, The unparalleled rise of obesity in China: a call to action, Int J Obes (Lond), 45, 921, 10.1038/s41366-021-00774-w · DOI
  6. Shi, 2022, Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials, Lancet, 399, 259, 10.1016/S0140-6736(21)01640-8 · DOI · Paper page
  7. Davies, 2021, Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, Lancet, 397, 971, 10.1016/S0140-6736(21)00213-0 · DOI · Paper page
  8. Garvey, 2022, Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial, Nat Med, 28, 2083, 10.1038/s41591-022-02026-4 · DOI · Paper page
  9. Kadowaki, 2022, Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial, Lancet Diabetes Endocrinol, 10, 193, 10.1016/S2213-8587(22)00008-0 · DOI · Paper page
  10. Rubino, 2022, Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial, JAMA, 327, 138, 10.1001/jama.2021.23619 · DOI · Paper page
  11. Steinberg, 2017, Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program, Diabetes Care, 40, 839, 10.2337/dc16-2684 · DOI · Paper page
  12. Wewer Albrechtsen, 2016, Glucagon-like peptide 1 receptor signaling in acinar cells causes growth-dependent release of pancreatic enzymes, Cell Rep, 17, 2845, 10.1016/j.celrep.2016.11.051 · DOI
  13. Rompianesi, 2017, Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis, Cochrane Database Syst Rev, 4
  14. Solomon, 2017, Diabetic retinopathy: a position statement by the American Diabetes Association, Diabetes Care, 40, 412, 10.2337/dc16-2641 · DOI
  15. Akil, 2022, Early worsening of retinopathy in type 1 and type 2 diabetes after rapid improvement in glycaemic control: a systematic review, Diabetes Ther, 13, 1, 10.1007/s13300-021-01190-z · DOI

Cited by

Sorted by citations

Metadata

Authors
Mu, Y., Bao, X., Eliaschewitz, F. G., Hansen, M. R., Kim, B. T., Koroleva, A., Ma, R. C. W., Yang, T., Zu, N., & Liu, M.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2024-03
Volume
12
Issue
3
Pages
184-195
ISSN
2213-8587
DOI
10.1016/s2213-8587(23)00388-1
Cited by
133
References
10
Language
en
Licence
Funders
Novo Nordisk (NCT04251156)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review